Protein Disulfide Isomerases (PDI) Inhibitor Screening Kit (Fluorometric)

Kits

貨號 Cat. No.
K840-100
規格 Size
K840-100
Sample Type
Chemical libraries 、 Small molecules

Description




Alternate Name : PDIA1 Inhibitor screening kit


 

Tag Line :


Simple, HTP compatible assay to screen/characterize Protein Disulphide Isomerase (PDI) inhibitors within 1 hr.


 

Storage Conditions: -20°C


 

Shelf life: 12 months


 

Summary :


A simple and high-throughput adaptable assay kit used to fluorometrically (Ex/Em = 440/490 nm) screen/study/characterize potential inhibitors of Protein Disuphide Isomerase (PDI) within 30 min.


 

Detection Method: Fluorescence (Ex/Em = 440/490 nm)


 

Features & Benefits:


Simple and High throughput adaptable
60 minutes short protocol
Detect using a fluorometer or fluorescence microplate reader.


 

Description:


Protein Disulfide Isomerases (PDI, EC: 5.3.4.1) constitute a thio-disulfide oxidoreductase family. PDI is abundant in the lumen of endoplasmic reticulum (ER). PDI plays an essential role in catalyzing the rearrangement of S-S bonds in proteins and functions as a chaperon. Recent studies show that PDI activity is essential for cancer cell survival and proliferation, and targeting the PDI activity with its inhibitors abrogates survival responses to ER stress in cancer cells. Thus, identification and development of PDI inhibitors represents an important approach in cancer therapy. In BioVision’s PDI Inhibitor Screening Kit, the PDI converts Insulin into its reduced form in the presence of Dithiothreitol (DTT). This reduced insulin binds to a fluorescent probe to generate an intensely fluorescent product (Ex/Em = 440/490 nm). In the presence of a PDI inhibitor, the reaction is impeded/abolished, resulting in a decrease or total loss of fluorescence. This assay kit can be used to screen/study/characterize the potential inhibitors of Protein Disulfide Isomerase. The assay is simple, high-throughput adaptable and can be performed within 60 min.


 





詢價 / 洽詢此產品 下載 PDF

回到產品列表

▲ LINE
諮詢